RxDoctor Payments Data

Scott Rice, DO

Family Medicine · North Augusta, SCNPI 1326601873

Payments from drug & device makers

$4,660in general payments, 2019–2025

Across 250 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$808
  • AbbVie$559
  • Pfizer$518
  • Novo Nordisk$382
  • Novartis$345
  • GSK$323
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,660 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$86,672
Medicare patients
199
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide75$101,855
OzempicSemaglutide51$90,894
FarxigaDapagliflozin Propanediol59$60,053
EliquisApixaban37$44,017
JardianceEmpagliflozin38$36,821
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$26,159
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,544
Pantoprazole Sodium125$1,532
Albuterol Sulfate HfaAlbuterol Sulfate52$1,382
Atorvastatin Calcium179$1,266
Rosuvastatin Calcium80$1,250
Omeprazole78$1,057
Levothyroxine Sodium112$994
Gabapentin94$863
Fluticasone Propionate47$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$289$101,85575 claims
Novo NordiskOzempic$382$90,89451 claims
AstraZenecaFarxiga, Breztri Aerosphere$808$86,21285 claims
PfizerEliquis$518$44,01737 claims
Boehringer IngelheimJardiance$203$36,82138 claims
GSKTrelegy Ellipta$323$10,54412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in North Augusta

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →